Skip to main content
Erschienen in: Der Diabetologe 3/2008

01.05.2008 | Leitthema

Therapeutische Möglichkeiten beim metabolischen Syndrom

verfasst von: Prof. Dr. A. Fritsche

Erschienen in: Die Diabetologie | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Therapie des metabolischen Syndroms (MS) beinhaltet eine multifaktorielle Strategie. Da die Ausprägung der verschiedenen Komponenten des MS jedoch sehr unterschiedlich sein kann, steht am Anfang der Therapie die Festlegung individueller Therapieziele. Diese sollten sowohl am Risikoprofil für metabolische und kardiovaskuläre Erkrankungen als auch an den übrigen Lebensumständen des Patienten orientiert sein. Im Zentrum der Therapie steht eine nichtpharmakologische Lebensstilintervention, die eine Steigerung der körperlichen Bewegung und eine Kalorienreduktion beinhaltet. Die Therapie sollte eine Reduktion des Übergewichts und der abdominellen Fettmasse zum Ziel haben, in deren Folge Hyperglykämie, Hypertension und Hyperlipidämie verbessert werden. Führt die Lebensstilintervention nicht zum Erreichen der Therapieziele, so sollte mit dem Einsatz einer pharmakologischen Therapie nicht gezögert werden. Hierbei ist meist eine Polypharmakotherapie nötig, die eine genaue Einschätzung und Beobachtung der Neben- und Wechselwirkungen der eingesetzten Medikamente erfordert.
Literatur
1.
Zurück zum Zitat Grundy SM (2007) Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient? Am J Med (Suppl 1) 120: S3–S8 Grundy SM (2007) Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient? Am J Med (Suppl 1) 120: S3–S8
2.
Zurück zum Zitat Assmann G, Nofer JR, Schulte H (2004) Cardiovascular risk assessment in metabolic syndrome: view from PROCAM. Endocrinol Metab Clin North Am 33: 377–392PubMedCrossRef Assmann G, Nofer JR, Schulte H (2004) Cardiovascular risk assessment in metabolic syndrome: view from PROCAM. Endocrinol Metab Clin North Am 33: 377–392PubMedCrossRef
3.
Zurück zum Zitat Stephens JW, Ambler G, Vallance P et al. (2004) Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? Eur J Cardiovasc Prev Rehabil 11: 521–528PubMedCrossRef Stephens JW, Ambler G, Vallance P et al. (2004) Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? Eur J Cardiovasc Prev Rehabil 11: 521–528PubMedCrossRef
4.
Zurück zum Zitat Gohlke H, Winter M, Karoff M, Held K (2007) CARRISMA: a new tool to improve risk stratification and guidance of patients in cardiovascular risk management in primary prevention. Eur J Cardiovasc Prev Rehabil 14: 141–148PubMedCrossRef Gohlke H, Winter M, Karoff M, Held K (2007) CARRISMA: a new tool to improve risk stratification and guidance of patients in cardiovascular risk management in primary prevention. Eur J Cardiovasc Prev Rehabil 14: 141–148PubMedCrossRef
5.
Zurück zum Zitat Bergmann A, Li J, Wang L et al. (2007) A simplified Finnish diabetes risk score to predict type 2 diabetes risk and disease evolution in a German population. Horm Metab Res 39: 677–682PubMedCrossRef Bergmann A, Li J, Wang L et al. (2007) A simplified Finnish diabetes risk score to predict type 2 diabetes risk and disease evolution in a German population. Horm Metab Res 39: 677–682PubMedCrossRef
6.
Zurück zum Zitat Schulze MB, Hoffmann K, Boeing H et al. (2007) An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care 30: 510–515PubMedCrossRef Schulze MB, Hoffmann K, Boeing H et al. (2007) An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care 30: 510–515PubMedCrossRef
7.
Zurück zum Zitat Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome–a new worldwide definition. Lancet 366: 1059–1062PubMedCrossRef Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome–a new worldwide definition. Lancet 366: 1059–1062PubMedCrossRef
8.
Zurück zum Zitat Grundy SM, Cleeman JI, Daniels SR et al. American Heart Association; National Heart, Lung, and Blood Institute (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735–2752PubMedCrossRef Grundy SM, Cleeman JI, Daniels SR et al. American Heart Association; National Heart, Lung, and Blood Institute (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735–2752PubMedCrossRef
9.
Zurück zum Zitat Thamer C, Tschritter O, Haap M et al. (2005) Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. Horm Metab Res 37: 246–251PubMedCrossRef Thamer C, Tschritter O, Haap M et al. (2005) Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. Horm Metab Res 37: 246–251PubMedCrossRef
10.
Zurück zum Zitat Tschritter O, Fritsche A, Thamer C et al. (2003) Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52: 239–243PubMedCrossRef Tschritter O, Fritsche A, Thamer C et al. (2003) Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52: 239–243PubMedCrossRef
11.
Zurück zum Zitat Rydén L, Standl E, Bartnik M et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD) (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28: 88–136PubMedCrossRef Rydén L, Standl E, Bartnik M et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD) (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28: 88–136PubMedCrossRef
12.
Zurück zum Zitat CDC Diabetes Cost-effectiveness Group (2002) Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287: 2542–2551CrossRef CDC Diabetes Cost-effectiveness Group (2002) Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287: 2542–2551CrossRef
13.
Zurück zum Zitat Orchard TJ, Temprosa M, Goldberg R et al. Diabetes Prevention Program Research Group (2005) The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142: 611–619PubMed Orchard TJ, Temprosa M, Goldberg R et al. Diabetes Prevention Program Research Group (2005) The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142: 611–619PubMed
14.
Zurück zum Zitat Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486–2489CrossRef Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486–2489CrossRef
15.
Zurück zum Zitat US Department of Agriculture and Department of Health and Human Services (2005) Dietary Guidelines for Americans. Washington/DC US Department of Agriculture and Department of Health and Human Services (2005) Dietary Guidelines for Americans. Washington/DC
16.
Zurück zum Zitat Fogli-Cawley JJ, Dwyer JT, Saltzman E et al. (2007) The 2005 Dietary Guidelines for Americans and risk of the metabolic syndrome. Am J Clin Nutr 86: 1193–1201PubMed Fogli-Cawley JJ, Dwyer JT, Saltzman E et al. (2007) The 2005 Dietary Guidelines for Americans and risk of the metabolic syndrome. Am J Clin Nutr 86: 1193–1201PubMed
17.
Zurück zum Zitat Joost HG (2006) Nutrigenomics. Scientific basis, status and perspectives of application. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 49: 1011–1019PubMedCrossRef Joost HG (2006) Nutrigenomics. Scientific basis, status and perspectives of application. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 49: 1011–1019PubMedCrossRef
18.
Zurück zum Zitat Weyrich P, Stefan N, Häring HU et al. (2007) Effect of genotype on success of lifestyle intervention in subjects at risk for type 2 diabetes. J Mol Med 85: 107–117PubMedCrossRef Weyrich P, Stefan N, Häring HU et al. (2007) Effect of genotype on success of lifestyle intervention in subjects at risk for type 2 diabetes. J Mol Med 85: 107–117PubMedCrossRef
19.
Zurück zum Zitat Riccardi G, Giacco R, Rivellese AA (2004) Dietary fat, insulin sensitivity and the metabolic syndrome. Clin Nutr 23: 447–456PubMedCrossRef Riccardi G, Giacco R, Rivellese AA (2004) Dietary fat, insulin sensitivity and the metabolic syndrome. Clin Nutr 23: 447–456PubMedCrossRef
20.
Zurück zum Zitat Thomas DE, Elliott EJ, Baur L (2007) Low glycaemic index or low glycaemic load diets for overweight and obesity. Cochrane Database Syst Rev 18: CD005105 Thomas DE, Elliott EJ, Baur L (2007) Low glycaemic index or low glycaemic load diets for overweight and obesity. Cochrane Database Syst Rev 18: CD005105
21.
Zurück zum Zitat Schulze MB, Liu S, Rimm EB et al. (2004) Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women. Am J Clin Nutr 80: 348–356PubMed Schulze MB, Liu S, Rimm EB et al. (2004) Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women. Am J Clin Nutr 80: 348–356PubMed
22.
Zurück zum Zitat Zivkovic AM, German JB, Sanyal AJ (2007) Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr 86: 285–300PubMed Zivkovic AM, German JB, Sanyal AJ (2007) Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr 86: 285–300PubMed
23.
Zurück zum Zitat Lindström J, Louheranta A, Mannelin M et al. Finnish Diabetes Prevention Study Group (2003) The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 26: 3230–3236PubMedCrossRef Lindström J, Louheranta A, Mannelin M et al. Finnish Diabetes Prevention Study Group (2003) The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 26: 3230–3236PubMedCrossRef
24.
Zurück zum Zitat Thamer C, Machann J, Stefan N et al. (2007) High visceral fat mass and high liver fat are associated with resistance to lifestyle intervention. Obesity (Silver Spring) 15: 531–538 Thamer C, Machann J, Stefan N et al. (2007) High visceral fat mass and high liver fat are associated with resistance to lifestyle intervention. Obesity (Silver Spring) 15: 531–538
25.
Zurück zum Zitat Grundy SM (2007) Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 92: 399–404PubMedCrossRef Grundy SM (2007) Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 92: 399–404PubMedCrossRef
26.
Zurück zum Zitat Fritsche A (2007) Guideline-compatible therapy with orl antidiabetic agents including the combination with insulin. Diabetologe 3: 24–30CrossRef Fritsche A (2007) Guideline-compatible therapy with orl antidiabetic agents including the combination with insulin. Diabetologe 3: 24–30CrossRef
27.
Zurück zum Zitat Nathan DM, Buse JB, Davidson MB et al. Professional Practice Committee, American Diabetes Association; European Association for the Study of Diabetes (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49: 1711–1721PubMedCrossRef Nathan DM, Buse JB, Davidson MB et al. Professional Practice Committee, American Diabetes Association; European Association for the Study of Diabetes (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49: 1711–1721PubMedCrossRef
28.
Zurück zum Zitat Nathan DM, Buse JB, Davidson MB et al. (2008) Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: Update regarding the thiazolidinediones. Diabetologia 51: 8–11PubMedCrossRef Nathan DM, Buse JB, Davidson MB et al. (2008) Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: Update regarding the thiazolidinediones. Diabetologia 51: 8–11PubMedCrossRef
29.
Zurück zum Zitat Aronne LJ (2007) Therapeutic options for modifying cardiometabolic risk factors. Am J Med (Suppl 1) 120: S26–S34 Aronne LJ (2007) Therapeutic options for modifying cardiometabolic risk factors. Am J Med (Suppl 1) 120: S26–S34
30.
Zurück zum Zitat Kakafika AI, Mikhailidis DP, Karagiannis A, Athyros VG (2007) The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol 47: 642–652PubMedCrossRef Kakafika AI, Mikhailidis DP, Karagiannis A, Athyros VG (2007) The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol 47: 642–652PubMedCrossRef
31.
Zurück zum Zitat Grundy SM (2006) Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 5: 295–309PubMedCrossRef Grundy SM (2006) Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 5: 295–309PubMedCrossRef
32.
Zurück zum Zitat Nicolucci A, De Berardis G, Sacco M, Tognoni G (2007) AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J 28: 1925–1927PubMedCrossRef Nicolucci A, De Berardis G, Sacco M, Tognoni G (2007) AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J 28: 1925–1927PubMedCrossRef
33.
Zurück zum Zitat Masulli M, Riccardi G, Galasso R, Vaccaro O (2006) Relationship between smoking habits and the features of the metabolic syndrome in a non-diabetic population. Nutr Metab Cardiovasc Dis 16: 364–370PubMedCrossRef Masulli M, Riccardi G, Galasso R, Vaccaro O (2006) Relationship between smoking habits and the features of the metabolic syndrome in a non-diabetic population. Nutr Metab Cardiovasc Dis 16: 364–370PubMedCrossRef
Metadaten
Titel
Therapeutische Möglichkeiten beim metabolischen Syndrom
verfasst von
Prof. Dr. A. Fritsche
Publikationsdatum
01.05.2008
Verlag
Springer-Verlag
Erschienen in
Die Diabetologie / Ausgabe 3/2008
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI
https://doi.org/10.1007/s11428-008-0226-7

Weitere Artikel der Ausgabe 3/2008

Der Diabetologe 3/2008 Zur Ausgabe

Magazinseite

Magazinseiten

Mitteilungen

Mitteilungen DDS

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

22.05.2024 Obstipation Nachrichten

Bei chronischer Verstopfung wirken Kiwis offenbar besser als Flohsamenschalen. Das zeigen die Daten aus einer randomisierten Studie, die der Gastroenterologe Oliver Pech beim Praxis-Update vorstellte.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.